11/7/26 Retention by Design - Keeping Families Engaged for Multi-Year Studies Previous Patient Input and Digital Health Technologies: A Regulatory Perspective Across the Product Lifecycle Next Bridging the Generational Divide in Rare Disease Clinical Trials: Tailoring Communication to Maximize Recruitment, Retention, and Equity You Might Also Like From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Who Really Decides Which Rare Disease Therapies Survive: Regulators, Investors, Payers, or Patients? OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients.
11/7/26 Retention by Design - Keeping Families Engaged for Multi-Year Studies Previous Patient Input and Digital Health Technologies: A Regulatory Perspective Across the Product Lifecycle Next Bridging the Generational Divide in Rare Disease Clinical Trials: Tailoring Communication to Maximize Recruitment, Retention, and Equity You Might Also Like From Data to Discovery: Finding the Right Patients Across the Therapy Lifecycle From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Who Really Decides Which Rare Disease Therapies Survive: Regulators, Investors, Payers, or Patients? OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients.
